Strict Advisory on GLP-1 Drugs for Diabetes and Obesity
The Indian government has issued a detailed advisory on GLP-1 receptor agonist drugs, emphasizing strict medical supervision, regulatory surveillance, and risks for type 2 diabetes and obesity treatment.


